CoChat

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52‐week open‐label, randomized phase III trial

Open access
Wang, Weiqing, Nevárez, Luis, Filippova, Ekaterina, Song, Ki Ho, Tao, Bei, Gu, Liqun, Wang, Feng, Li, Pengfei, Yang, Jun · 2019 · Diabetes, Obesity and Metabolism
Cited by 51

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aim: To compare the efficacy and safety of once‐weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM). Materials and Methods: In this 52‐week, randomized, parallel‐arm open‐label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%). The primary outcome was change in HbA1c from baseline to week 26 to determine non‐inferiority of dulaglutide 1.5 mg versus glargine. Results: A total of 774 patients from China, South Korea, Mexico and Russia were randomly assigned (1:1:1) to dulaglutide 1.5 mg, dulaglutide 0.75 mg or glargine treatment groups. The patients' mean age was 55 years and the average T2DM duration was ~8 years. The least squares mean (SE) changes from baseline in HbA1c at 26 weeks were − 18.9 (0.73) mmol/mol (−1.73 [0.067]%) for dulaglutide 1.5 mg and −14.5 (0.73) mmol/mol (−1.33 [0.067]%) for dulaglutide 0.75 mg, compared with −12.7 (0.73) mmol/mol (−1.16 [0.067]%) for glargine. Statistical criteria for superiority were met with both dulaglutide 1.5 mg and dulaglutide 0.75 mg. More patients in the dulaglutide 1.5 and 0.75 mg groups achieved HbA1c target <53.0 mmol/mol (<7.0%) than in the glargine group at week 26 ( P < 0.001 and P = 0.004, respectively). Body weight decreased with dulaglutide and increased with glargine. The incidence and rate of total hypoglycaemia were lower with dulaglutide versus glargine. Gastrointestinal adverse events, including diarrhoea and nausea, were the most frequently reported for patients taking dulaglutide. Conclusions: Once‐weekly dulaglutide provides greater improvement in HbA1c, with weight loss and less hypoglycaemia, than once‐daily insulin glargine in a population of mainly Asian patients with T2DM who had failed to achieve optimal glycaemic control on metformin and/or a sulphonylurea.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13506

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 18

  1. International Diabetes Federation, 2017, IDF Diabetes Atlas
  2. Diabetes Care 2015 38 suppl 1 Standards of medical care in diabetes–2015: summary of revisions · DOI · Paper page
  3. 10.4158/EP.12.S1.71 · DOI
  4. 10.1007/s00125-014-3360-3 · DOI
  5. 10.2337/dc13-2759 · DOI · Paper page
  6. 10.1016/S0140-6736(15)60936-9 · DOI · Paper page
  7. 10.1111/dom.12575 · DOI
  8. 10.1111/dom.12540 · DOI · Paper page
  9. 10.1016/j.diabres.2007.08.007 · DOI
  10. 10.1002/bimj.200710464 · DOI · Paper page
  11. Westfall PH, 1993, Resampling‐Based Multiple Testing: Examples and Methodsforp‐Value Adjustment
  12. 10.1016/j.diabres.2006.08.012 · DOI
  13. 10.2337/dc10-1701 · DOI
  14. 10.1056/NEJMc1004671 · DOI · Paper page
  15. 10.1097/00029330-200811010-00002 · DOI
  16. 10.1111/dme.13437 · DOI
  17. 10.1210/en.2014-1717 · DOI · Paper page
  18. 10.1111/dom.12640 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Wang, W., Nevárez, L., Filippova, E., Song, K. H., Tao, B., Gu, L., Wang, F., Li, P., & Yang, J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-10-07
Volume
21
Issue
2
Pages
234-243
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2888666511
Cited by
51
References
12
FWCI
3.92
Type
journal article
Language
en
Open access
hybrid
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.